Akers Biosciences Inc (LON:AKR, NASDAQ:AKER) is celebrating a milestone after the company trumpeted a major US distribution deal for its cholesterol self-testing kit.
The developer of rapid health information technologies has signed a distribution agreement with First Check Diagnostics, the major global diagnostic device and service provider.
Co-founder ray Akers tells Proactive: ”Even my bad cold today can’t dampen the excitement of this news. This is a major, major win for Akers Bio”
First Check will rebadge the Akers Tri-Cholesterol “Check” test and distribute it exclusively in the US under the “First Check” brand. The test does not require US Food & Drug Administration approval so it can be sold over the counter.
Akers adds: ”We’re happy to bring our shareholders good news and we know we have many, many more pieces of good news to follow.”
Story by ProactiveInvestors